Prediction of *BRCA1* and *BRCA2* mutations by the BODICEA and BRCAPRO models and NCCN criteria in Libyan breast cancer women

Eanas Elmaihub[1,#a], Inas Alhudiri[2], Adam Elzagheid[2], Fakria Elfagi[3] and Elham Hassen[1,4*]

[1]Department of Molecular biology, Higher Institute of Biotechnology of Monastir, Monastir University, Monastir, Tunisia.

[2]Department of Genetic Engineering, Libyan Biotechnology Research Centre, Tripoli, Libya.

[3]Department of Oncology, National Cancer Institute, Sabratha, Libya.

[4]laboratory of Molecular Immuno-Oncology, Faculty of Medicine, Monastir University, Monastir, Tunisia.

[#a]Department of Molecular biology and Biochemistry, Faculty of Sciences, Sabratha University, Sabratha, Libya.

*** Corresponding author: Elham Hassen**

E-mail: elhamhassenisbm@gmail.com elham.hassen@isbm.rnu.tn

Abstract

The *BRCA* mutation spectrum of familial breast cancer in Libya remains unknown. Several genetic models developed to predict the probability of *BRCA1/2* mutations have not been applied in Libya, where the NCCN criteria are used for highly penetrating breast cancer susceptibility genes. We aimed to predict *BRCA1/2* mutation probability in familial breast cancer and eligibility for genetic testing by using BOADICEA and BRCAPRO models and NCCN criteria. *BRCA1/2* mutations were retrospectively predicted in 62 unrelated women with familial breast cancer between 2018 and 2021. Logistic regression, ROC analysis and AUC were used to compare NCCN referral criteria with the BRCAPRO and BOADICEA scores. Of 62 breast cancer patients, 32 (51.6%) (mean age 43.5±8 years) were predicted by both models as *BRCA* mutation carriers. BRCAPRO predicted *BRCA1* and *BRCA2* mutations in 27.4% and 41.9% of the women, respectively. BOADICEA predicted 8% for *BRCA1* and 29% for *BRCA2*. At least one NCCN criterion was met by 50/62 women (80.6%). Only two criteria were statistically significant predictors in BRCAPRO and BOADICEA: breast cancer at ≤ 50 years with one or more close blood relatives with breast cancer, and breast cancer patient with a close relative of male breast cancer. For the two respective criteria, sensitivity was 0.78 and 0.89, specificity 0.33 and 0.39, AUC 0.72 and 0.75, PPV 78% and 27.5%, and NPV 67% and 97%. BODICEA and BRCAPRO models are suitable for recommending genetic testing for BRCA gene mutations. The NCCN criteria are too broad.

Keywords: Breast cancer, NCCN criteria, BRCAPRO, BOADICEA, *BRCA1*, *BRCA2*

Introduction

Women with germline mutations in the breast cancer susceptibility genes *BRCA1/2* have a 45–65% lifetime risk of developing breast cancer (BC) [1], and the prevalence of *BRCA* mutations in breast cancer patients is estimated to be 5–10% [2-7]. The lifetime risk in the presence of germline mutations is probably tenfold greater than in the general population. This risk may be reduced by surgical interventions such as bilateral prophylactic mastectomy, which reduces the risk of BC by more than 90% [7-10]. Cancer susceptibility gene testing can identify individuals who are most likely to benefit from risk-reduction interventions.

Genetic testing of *BRC1* and *BRC2* is costly and difficult to interpret, particularly in families with a low likelihood of having a mutation. Therefore, it is important to estimate the likelihood that a family carries a *BRCA1/2* gene mutation before a genetic test is done [11].

In several countries, a clinical standard for identifying hereditary breast/ovarian cancer has been developed and data have accumulated [2, 8]. This has resulted in the development of various models [3, 12- 14] that can more precisely estimate *BRCA1/2* mutation carrier probabilities based on both genetic and empirical models that calculate the probability of mutation by using predictor variables derived from cancer family history. The BRCAPRO software [13, 15] and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) are examples of such tools [16, 17]. BOADICEA was founded by women and families from the United Kingdom, as well as a few other countries, and Africans are not represented.

Furthermore, BRCAPRO is based on mutation rates and penetrance in women of Ashkenazi Jewish and European ancestry [4, 18].

Libya lacks genetic testing for familial and non-familial mutations in cancer patients, including breast cancer [19], and most of those who require it must travel abroad. Consequently, familial breast and ovarian cancer patients in Libya are assessed based on the National Comprehensive Cancer Network (NCCN) criteria for highly penetrating breast cancer susceptibility genes. In addition, the *BRCA1/2* gene testing is typically recommended only for patients who are triple-negative and have a family history of breast/ovarian cancer. Despite the utility of the NCCN criteria for referral to genetic assessment, they lack specificity for accurately excluding people with low *a priori* risk [20]. In light of these issues, the logical step would be to develop local protocols that are efficient, practical, and beneficial to those specific patients.

To the best of our knowledge, *BRCA1/2* mutation prediction models have not been applied in people of North African ethnicity. Hence, we aimed to retrospectively predict *BRCA1/2* mutation probability in Libyan women with BC by using the BOADICEA and BRCAPRO models, and to compare how the NCCN high risk assessment criteria perform in referring BC patients for genetic evaluation in comparison to the two risk assessment models.

Methods

Ethics Statements

The study was approved by the Research Ethics Committee of the National Cancer Institute (NCI), Sabratha, Libya. Verbal informed consent was obtained from each patient before recruitment in the study.

Patients and criteria

The study included 62 unrelated women with BC who were followed up at the outpatient clinic of the National Cancer Institute in Sabratha, Libya from 2018 to 2021. The patients were selected based on a family history of breast, ovarian or other cancer in one or more first- second- or third- degree relatives regardless of the age of onset. Data were collected from the patients in a self-administered questionnaire during their visits to the clinic. The medical records of the patients were reviewed.

Study tools

To calculate the probability of a patient being a *BRCA1/2* mutation carrier, we used the BRCAPRO CancerGene software program (v6, BayesMendel R package) (http://www4.utsouthwestern.edu/breasthealth/cagene) and BOADICEA CanRisk v2.2.0 (https://www.canrisk.org/).

BRCAPRO uses statistical ideas that go back to Bayes and Mendel [15]. It analyzes data from patients and all their relatives, including their age at diagnosis, current age, age at death, ethnicity, BC markers such as estrogen, progesterone and HER2 receptor scores, and other risk factors such as the woman's age at first live birth, and mammographic density. The computations make use of information on breast, ovarian, and other cancer occurrences among first- and second-degree relatives.

BOADICEA uses information such as lifestyle, women's health, number and sex of children, breast screening, mammographic density, reproductive factors, and medical and family history. The medical history of the patients included age at diagnosis of breast or ovarian cancer. The family history included age at diagnosis of breast, ovarian, pancreatic or prostate cancer in first or second-degree relatives. In our study, ethnicity of all the patients was marked as "unknown" in BRCAPRO and as "other" in BOADICEA because of insufficient research on the ethnic groups living in North Africa. Based on the probability calculation scores in the two models, ≥ 10% was considered a high-risk subgroup that would benefit from genetic testing [21].

The patients were also assessed using the National Comprehensive Cancer Network NCCN criteria (v2.2022) for referral to genetic risk evaluation [22]. NCCN does not provide a percent probability of mutation, whereas the models calculate carrier probability scores for the *BRCA1* and *BRCA2* genes separately.

We compared each of the NCCN referral criteria to the BRCAPRO and BOADICEA scores of our breast cancer patients to determine how each of the NCCN criteria performed.

Statistical analysis

We summarized the clinical characteristics of the study participants as medians for continuous variables and frequencies for categorical variables. Logistic regression was used in conjunction with receiver operating characteristic (ROC) analysis to determine which NCCN criteria were statistically significant predictors of high-risk patients, and the BRCAPRO and/or BOADICEA were used as the reference standards to evaluate the

sensitivity and specificity of the patient's criteria. Area under the curve (AUC), a general indicator of accuracy, was measured using ROC curves and the calculations were made for both positive predictive values (PPV) and negative predictive values (NPV). A test that is perfect has an area of 1, whereas an area of 0.5 means that the test is useless. We examined each of the NCCN referral criteria in relation to the BRCAPRO and BOADICEA results of our breast cancer patients to see how each of the NCCN criteria performed. The clinical significance of each NCCN criterion was determined by BRCAPRO and/or BOADICEA scoring. All statistical analyses were performed with IBM SPSS Statistics v20.

Results

The clinical characteristics of the 62 BC women who participated in the study are summarized in Table 1. Forty-eight (77%) of them were ≤ 50 years old at diagnosis, with an average of 44.8 years. Thirty-eight women (61.2%) had a family history of BC in first-degree relatives and 13 (21%) in second-degree relatives.

From the BRCAPRO and BOADICEA model scores based on the information provided by the patients, the highest prediction rates were 90.8% for *BRCA2* and 75.7% for *BRCA1*. The mean carrier probability for all mutations in BRCAPRO was 8.1% for *BRCA1* and 18.7% for *BRCA2*. For BOADICEA it was 4.8% for *BRCA1* and 12.3% for *BRCA2*. Using a cutoff of ≥ 10%, BOADICEA identified 5/62 (8%) of the patients as having a high risk of *BRCA1* mutations and 18/62 (29%) as high-risk for *BRCA2* mutations, whereas BRCAPRO identified 17/62 (27.4%) for *BRCA1* and 26/62 (41.9%) for *BRCA2*. Consequently, 32/62 (51.6%) of the patients were identified as high risk by BOADICEA

and/or BRCAPRO and therefore eligible for genetic testing. Four individuals had high risk in both models of *BRCA1*, 13 had high risk in BRCAPRO only, and 1 had high risk in BOADICEA only. For *BRCA2*, 15 patients were positive in both models at the same threshold, 11 were positive in BRCAPRO, and 3 were positive in BOADICEA.

Table 1 Patient characteristics

Characteristic	**(%) Frequency**
≤ 50 y	48 (77)
Family history of breast cancer in	
1st degree relatives	38 (61.2)
2nd degree relatives	13 (21)
3rd degree relatives	8 (13)
Family history of ovarian cancer in	
1st degree relatives	1 (1.6)
Family history of prostate or pancreas cancer	4(6.4**)**
Family history of endometrium cancer in	
1st degree relatives	4(6.4)

The average ages (mean ± SD) of patients classified as high risk for *BRCA1* mutations by BRCAPRO and BOADICEA were, respectively, 42.5 ± 9.5 years and 43.6 + 14.8 years. For both models together, it was 42.7 ± 9.2 years. The mean age of patients identified as having low risk of *BRCA1* mutations by these models was 45.1 ± 8.9 years (p = 0.7). On the other hand, the average ages of patients with high risk of *BRCA2* mutation by BRCAPRO, BOADICEA, both models and low risk BRCA2 mutations were 42.12 ± 7.8 years, 43.5 ± 9.6, 43.6 ± 8.4 and 45.8 ± 9.2, respectively (p = 0.8).

Table 2 shows the results for 50/62 (80.6%) patients who met at least one NCCN criterion. Using logistic regression, one NCCN criterion (BC patient at age ≤ 50 with one or more BC close blood relatives) was a statistically significant predictor of

patients identified as high risk for *BRCA1* and *BRCA2 2* mutations by either BRCAPRO or BOADICEA score (p = .011 and p = .005 respectively) in with sensitivity of 0.78, specificity of 0.33, and area under the ROC curve of 0.72 (Fig 1). PPV was 78% and NPV was 67%. The criterion of BC patient with relative male BC was statistically significant in patients at high risk of *BRCA2* mutations (P = .023), with sensitivity of 0.89, specificity of 0.39, and area under the ROC curve of 0.75 (Fig 2). PPV was 27.5 % and NPV was 97%.

Table 2 BRCAPRO and BODICEA models against NCCN criteria for prediction of mutation risk in *BRCA1/2* genes

NCCN Criteria A woman with BC diagnosis meeting any of :the following	No. of patients	BRCAPRO patients score ≥ 10		BODICEA patients score ≥ 10		High score by BRCAPRO or BOADICEA		P value for high score by BRCAPRO or BOADICEA	
		BRCA1 N = 17	BRCA2 N = 26	BRCA1 N = 5	BRCA2 N = 18	BRCA1 N = 18	BRCA2 N = 29	BRCA1	BRCA2
BC at age ≤ 50 and ≥ 1 close blood relative with B or O C age ≤ 50	35	14	22	4	14	15	23	**.011 ***	**.005 ***
At age 45≤	10	1	1	0	0	1	1	. 178	.031
Double primary BC/ OC	2	1	2	1	1	1	2	.487	.999
Male BC relative	9	4	9	0	6	4	9	.279	**.023 ***
≥ 1 relative with prostate or pancreatic cancer	4	0	1	0	1	0	1	.999	.385

Triple negative (ER, PR, Her2-) BC diagnosed ≤60 years old	4	1	0	1	1	2	1	.336	.420

Twelve patients did not meet any of the NCCN criteria.

Breast B, Ovary O, Cancer C, * Significant.



Fig 1. ROC curve for NCCN criterion of BC at age ≥ 50 years and one or more close blood relatives with breast or ovarian cancer at age ≥ 50 years as predictor for genetic test eligibility.



Fig. 2 ROC curve for NCCN criterion: BC patients with relatives of male BC as predictor of genetic test eligibility.

Discussion

Despite recent efforts by Libyan health authorities to develop nationwide breast cancer screening programs [23], the unavailability of genetic diagnostics for people with familial breast and ovarian cancer remains a concern. Prediction of *BRCA* mutations in Libyan women has not been practiced, and this is the first study to use the BRCAPRO and BOADICEA scoring (≥ 10%) to predict *BRCA1/2* gene mutations in women with BC who have a strong family history of BC, and to evaluate the efficacy of NCCN criteria.

Based on the BRCAPRO and BOADICEA scoring systems, our calculated frequency of patients at high risk of being carriers of *BRCA1* and *BRCA2* mutations was 29% and 46.8% for the respective scoring systems. If these high-risk patients were to test positive for *BRCA1/2* mutations, this estimate would be consistent with studies showing that *BRCA2* mutations are more common than *BRCA1* mutations in the Arab region [24], though this pattern is not observed in the majority of other populations [25] We also found that the occurrence of both breast and ovarian cancer in one patient was related to a high risk of a *BRCA1* mutation, as reported in Sweden [26]. This patient had the highest probability of *BRCA1* mutation in the BODICEA model.

We employed BRCAPRO and BOADICEA because they have been shown to be the most reliable in predicting mutant carrier probability when compared to other scoring models [27]. BRCAPRO predicted that 27.4% of the patients had *BRCA1* mutations and 41.9% had *BRCA2* mutations, which are slightly greater than the percentages predicted by BOADICEA (8% for *BRCA1* and 29% for *BRCA2*). The BRCAPRO model is

similar to BOADICEA in that *BRCA1* and *BRCA2* are modeled independently. The differences between them can be explained in part by their use of different mutation rates and allele frequencies. In particular, in BRCAPRO, the mutations are assumed to be more common in *BRCA1* than in *BRCA2*, but BOADICEA finds that *BRCA1* and *BRCA2* mutations have similar population frequencies, though *BRCA2* was more common [28]. The benefit of using two predictive models instead of one was that we were able to identify more high-risk patients who needed genetic testing, and based on score results from either or both scoring systems, we recorded 13 more *BRCA1* and 11 more *BRCA2* high risk patients compared to using either system alone.

The overall mutation prevalence in patients identified as high risk by BRCAPRO and BOADICEA was lower than would be expected based on the NCCN criteria. The NCCN criteria that correlated best with the scoring systems for identifying high-risk patients were BC patients at age ≥ 50 years and one or more close blood relatives with cancer at age ≥ 50 years and BC patients with relatives of male BC which had high sensitivity of %78 and 89% and low specificity 33% and 39% in respectively. This could result in a large number of patients with a low likelihood of having a *BRCA* mutation being referred for a genetic test. Though the P value of BC patients with *BRCA2* at age ≥45 years was .032 it had a poor area under the ROC curve (0.4), indicating that the criterion may not differentiate between high- and low-risk BRCA mutation carriers, especially because it depends on patient age alone. The other criteria (double primary BC, one or more relatives with prostate or pancreatic cancer, and triple-negative BC) were not significant, possibly due to small sample size.

Our study has some limitations. We hypothesized that a BRCAPRO or BOADICEA cutoff of ≥ 10% would be enough to predict the presence of a *BRCA* mutation in patients who require a genetic test with acceptable false-negative rates. We also could not compensate for the fact that none of our patients had a genetic test. However, this study aims to make a pretest prediction of *BRCA1* and *BRCA2* carrier mutations. We also had low number of patients with double primary BC, double primary BOC, BC patients with relatives who had prostate or pancreatic cancer, and triple negative (ER, PR, Her2) BC patients at the age of 60. As a result, increasing the number of patients who meet the rarer criteria will improve the statistical analysis of that criterion.

Conclusion

The NCCN criteria for making decisions on genetic testing have shortcomings because some of them are too general. Based on our results, we believe that using *BRCA* risk calculator models such as BRCAPRO and BODICEA will be advantageous for identifying high risk patients**.**

Acknowledgement

We appreciate the help received from the Sabratha Research Unit of the National Cancer Institute and the Oncology Department.

Author contributions

Conceptualization: Eanas Elmaihub, Inas Alhudiri

Data curation: Eanas Elmaihub, Fakria Elfagi

Formal analysis: Eanas Elmaihub

Investigation: Eanas Elmaihub, Fakria Elfagi

Methodology: Eanas Elmaihub, Inas Alhudiri

Supervision: Elham Hassen, Adam Elzagheid

Writing – original draft: Eanas Elmaihub

Writing – review & editing: Elham Hassen, Inas Alhudiri

Funding None

Competing interests None declared.

References

1. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Journal of Medical Genetics. Jul 2008; 45:425-431.
2. Balmana J, Diez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2011 Sep 1;22:vi31-4. doi: 10.1093/annonc/mdr373.
3. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of Clinical Oncology. 2002 Mar 15;20(6):1480-90. doi: 10.1200/JCO.2002.20.6.1480
4. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined

analysis of 22 studies. The American Journal of Human Genetics. 2003 May 1;72(5):1117-30. https://doi.org/10.1086/375033.

5. Myriad Genetic Laboratories, Inc**.** Mutation prevalence tables for BRCA1/2 genes. 2010. http://www.myriadtests.com/provider/brca_mutation_prevalence.htm.

6. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US Preventive Services Task Force. Annals of internal medicine. 2005 Sep 6;143(5):362-79. https://doi.org/10.7326/0003-4819-143-5-200509060-00012.

7. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar; 22(6):1055–1062. doi: 10.1200/JCO.2004.04.188.

8. Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, et al. Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: the ABOUT study. JAMA oncology. 2015 Dec 1;1(9):1251-60. https://doi.org/10.1001/jamaoncol.2015.3048.

9. Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ. et al. test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value in Health. 2017 Apr 1;20(4):547-55. https://doi.org/10.1016/j.jval.2017.01.006.

10. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral

mastectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine. 2001 Jul 19;345(3):159-64. doi: 10.1056/NEJM200107193450301.

11. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003 Jun 15;21(12):2397-406. doi: 10.1200/JCO.2003.03.189.
12. Couch FJ, Deshano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL, Jablon L, Cobleigh MA. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New England Journal of Medicine. 1997 May 15;336(20):1409-15. doi: 10.1056/NEJM199705153362002.
13. Berry DA, Iversen Jr ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology. 2002 Jun 1;20(11):2701-12. doi: 10.1200/JCO.2002.05.121.
14. Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Journal of medical genetics. 2004 Jun 1;41(6):474-80. http://dx.doi.org/10.1136/jmg.2003.017996.
15. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute. 1997 Feb 5;89(3):227-37. https://doi.org/10.1093/jnci/89.3.227.

16. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British journal of cancer. 2008 Apr;98(8):1457-66. https://doi.org/10.1038/sj.bjc.6604305.

17. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. British journal of cancer. 2002 Jan;86(1):76-83. https://doi.org/10.1038/sj.bjc.6600008.

18. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, et al. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. Jama. 2005 Oct 19;294(15):1925-33. doi:10.1001/jama.294.15.1925.

19. Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O, Radouani F. Genetics of breast cancer in African populations: a literature review. Glob Health Epidemiol Genom. 2018 May 11;3:e8. doi: 10.1017/gheg.2018.8. PMID: 30263132; PMCID: PMC6152487.

20. Lim GH, Borje E, Allen Jr JC. Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic. Gland Surgery. 2017 Feb;6(1):35. https://doi.org/10.21037%2Fgs.2016.11.05

21. Varesco L, Viassolo V, Viel A, Gismondi V, Radice P, Montagna M, Alducci E, Della Puppa L, Oliani C, Tommasi S, Caligo MA, Vivanet C, Zuradelli M, Mandich

P, Tibiletti MG, Cavalli P, Lucci Cordisco E, Turchetti D, et al. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. Breast. 2013 Dec;22(6):1130-5. doi: 10.1016/j.breast.2013.07.053. Epub 2013 Sep 5. PMID: 24011770.

22. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Genetic/Familial High-Risk Assessment: Breast and Ovarian. National Comprehensive Cancer Network; version 2.2022 Available online: https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/nccn-clinical-practice-genetic.pdf, accessed March 9, 2022.
23. ElJilani MM, Shebani AA, Bishr AM, Jalil HM, Dalyoum TM, Abudalla HA, et al. Assessment of breast cancer risk in Libyan women using the Gail model. Libyan Journal of Medical Sciences. 2020 Jul 1;4(3):115. DOI: 10.4103/LJMS.LJMS_26_20.
24. Abdulrashid K, AlHussaini N, Ahmed W, Thalib L. Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC cancer. 2019 Dec;19(1):1-2. https://doi.org/10.1186/s12885-019-5463-1.
25. Riahi A, Ghourabi ME, Fourati A, Chaabouni-Bouhamed H. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families. Breast Cancer. 2017 Mar;24(2):238-44. https://doi.org/10.1007/s12282-016-0693-4

26. Einbeigi Z, Bergman A, Meis-Kindblom JM, Flodin A, Bjursell C, Martinsson T, et al. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. Familial cancer. 2007 Mar;6(1):35-41. https://doi.org/10.1007/s10689-006-9101-0.

27. Hung FH, Wang YA, Jian JW, Peng HP, Hsieh LL, Hung CF, et al. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan. Sci Rep. 2019 Jul 15;9(1):10229. doi: 10.1038/s41598-019-46707-6.

28. Berry DA, Iversen Jr ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology. 2002 Jun 1;20(11):2701-12. doi: 10.1200/JCO.2002.05.121



Fig 1. ROC curve for NCCN criterion of BC at age ≥ 50 and one or more close blood relatives with breast cancer at age ≥ 50 years as predictor for genetic test eligibility



Fig. 2 ROC curve for NCCN criterion: BC patients with relatives of male BC as predictor of genetic test eligibility.